XSHE
002788
Market cap615mUSD
Oct 09, Last price
10.71CNY
1D
1.04%
1Q
4.18%
Jan 2017
-50.30%
IPO
-0.74%
Name
Luyan Pharma Co Ltd
Chart & performance
P/E
14.81
P/S
0.20
EPS
0.72
Div yield, %
3.30%
Shrs. gr., 5y
0.07%
Rev. gr., 5y
3.90%
Revenues
21.25b
+3.79%
Net income
281m
-18.74%
CFO
688m
+19.21%
Dividend
Jul 10, 20260.35 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Luyan Pharma Co.,Ltd. is a Chinese enterprise dedicated to the complete lifecycle of human health products, from their initial research and development through manufacturing and ultimate market distribution. Additionally, the company manages its own pharmaceutical distribution channels and a network of direct retail pharmacies. Originally established as Luyan (Fujian) Pharma Co. Ltd., the firm rebranded and adopted its current name, Luyan Pharma Co.,Ltd., in June 2016. This company was founded in 1992 and maintains its principal offices in Xiamen, China.
Key people
Weiyang Li
Deputy General Manager
Junying Zhang
Deputy General Manager
Chongbin Zheng
Deputy General Manager
Ming Guo Zhu
Deputy General Manager, Director
Ming Lei
Deputy General Manager, Secretary of the Board, Director
Min Li
Director
Jinxiang Wu
Chairman of the Board, General Manager
Congjin Yang
Chief Financial Officer, Director
Independent Director
Junlong Wu
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||